Canada Life’s Lineage Cell Therapeutics LCTX Stock Holding History

Canada Life’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,000	Closed	-$6K	–	2786
2019 Q1	$6K	Hold	5,000	–	–	﹤0.01%	2424
2018 Q4	$4K	Sell	5,000 -715	-13%	-$1.09K	﹤0.01%	2623
2018 Q3	$12K	Hold	5,715	–	–	﹤0.01%	2535
2018 Q2	$10K	Hold	5,715	–	–	﹤0.01%	2548
2018 Q1	$13K	Hold	5,715	–	–	﹤0.01%	2525
2017 Q4	$11K	Hold	5,715	–	–	﹤0.01%	2518
2017 Q3	$14K	Hold	5,715	–	–	﹤0.01%	2513
2017 Q2	$16K	Hold	5,715	–	–	﹤0.01%	2513
2017 Q1	$17K	Hold	5,715	–	–	﹤0.01%	2475
2016 Q4	$18K	Sell	5,715 -27,318	-83%	-$83.9K	﹤0.01%	2500
2016 Q3	$112K	Hold	33,033	–	–	﹤0.01%	2093
2016 Q2	$75K	Hold	33,033	–	–	﹤0.01%	2202
2016 Q1	$83K	Sell	33,033 -2,774	-8%	-$6.19K	﹤0.01%	1898
2015 Q4	$119K	Hold	35,807	–	–	﹤0.01%	1636
2015 Q3	$87K	Buy	35,807 +28,373	+382%	+$73.5K	﹤0.01%	1805
2015 Q2	$26K	Buy	+7,434	New	+$28.8K	﹤0.01%	2401

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Canada Life's LCTX Position: Q2 2019 in Review

Canada Life sold out of Lineage Cell Therapeutics (LCTX) in Q2 2019, closing a stake of 5,000 shares — an estimated $6K sold.

Canada Life first reported a position in LCTX in Q2 2015 and held it in 16 quarters. The position peaked at $119K in Q4 2015. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2019.

Canada Life reported no remaining Lineage Cell Therapeutics position as of Q2 2019 after selling out during the quarter.
Canada Life sold 5,000 Lineage Cell Therapeutics shares in Q2 2019, an estimated $6K.
Canada Life first reported a position in Lineage Cell Therapeutics in Q2 2015 and held it in 16 quarters.
Canada Life's Lineage Cell Therapeutics position peaked at $119K in Q4 2015.
107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2019.

Based on Canada Life's 13F filing for Q2 2019, filed 31 Jul 2019.